Aptose Biosciences to reschedule special meeting

Executive Summary

• Aptose Biosciences Inc. is rescheduling its Special Meeting of Shareholders, originally set for January 16, 2026, to a later date in January 2026 pending final clearance of the proxy statement from the U.S. Securities and Exchange Commission (SEC).
• The meeting remains focused on approving the continuance of the company from the Canada Business Corporations Act to the Business Corporations Act (Alberta) and the subsequent acquisition by HS North America Ltd., a wholly owned subsidiary of Hanmi Pharmaceutical Co. Ltd.
• The Board of Directors unanimously recommends that shareholders vote in favor of the special resolutions approving the continuance and the arrangement.

Key Details

• Meeting Rescheduling: The special meeting of shareholders is moved from January 16, 2026, to a later date in January 2026 to be announced after SEC clearance.
• Record Date: The record date for the meeting remains unchanged at the close of business on December 12, 2025.
• Transaction Details:
  • Target: HS North America Ltd. (wholly owned subsidiary of Hanmi Pharmaceutical Co. Ltd.).
  • Structure: Acquisition by way of a statutory plan of arrangement under the Business Corporations Act (Alberta).
  • Preceding Action: Continuance of Aptose from the Canada Business Corporations Act to the Business Corporations Act (Alberta).
• Regulatory Status: The company received an interim order from the Court of King's Bench of Alberta on December 12, 2025, authorizing the holding of the meeting. The rescheduling is specifically due to pending final clearance of the proxy statement from the SEC.
• Disclosure: Aptose intends to mail proxy statements, forms of proxy, and letters of transmittal to shareholders and make them available on SEDAR+ and EDGAR.

Notable Quotes

• "The company's board of directors unanimously recommends that the holders of Aptose common shares vote for the special resolutions approving the continuance and the arrangement at the meeting."